AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04656340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-medication, non-interventional therapies
Description: non-medication, non-interventional therapies
Study NCT04656340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-medication, non-interventional therapies
Description: non-medication, non-interventional therapies
Study NCT02402647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy (ET)
Description: The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
Study NCT00100178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control for Daclizumab (DZB)
Description: saline intravenous infusions
Study NCT03458962 — intervention group
Intervention type: GENETIC
Intervention: Genetic Enrollees
Description: Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
Study NCT02477839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
Study NCT02477839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
Study NCT01285453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadimezan
Study NCT02781779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverlon®
Description: Silverlon wound dressings
Study NCT02781779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® AG
Description: AQUACEL® AG wound dressings
Study NCT02626767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel high-intensity interval exercise training
Description: Please see information already included in the 'intervention' arm description.
Study NCT02268955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ibuprofen
Description: Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
Study NCT02268955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered to the placebo group
Study NCT01287078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Inhalation Solution
Description: sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
Study NCT02216786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Oral tablet
Study NCT02216786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Oral tablet
Study NCT02216786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Im injection
Study NCT02216786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Im injection
Study NCT02121574 — intervention group
Intervention type: DEVICE
Intervention: Zero flux and ingestible thermometers
Study NCT02646592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
Study NCT04274387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction(MBSR)
Description: A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
Study NCT01173757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
Study NCT03701126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Dose 1ml /kg of patient body weight
Study NCT03701126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-sound guidance
Description: using superficial high frequency probe to guide regional anesthesia
Study NCT01955356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scratching
Description: Endometrial biopsy
Study NCT02646592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane or propofol
Study NCT02109393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT
Description: It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks.
Study NCT02109393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT+Lokomat
Description: It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
Study NCT04349384 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal resection
Description: Colon or rectal resection for colorectal adenocarcinoma
Study NCT03331328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MonaLisa Touch
Description: MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
Study NCT03331328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MonaLisa Touch
Description: MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
Study NCT00389519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: once a day oral ramipril capsules given for 4 weeks
Study NCT00389519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once a day oral placebo capsule for 4 weeks
Study NCT01045317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04776548
Description: single intravenous or oral administration of 0.1mg PF-04776548.
Study NCT03528954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Those who received intravenous propofol
Study NCT03425539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
Study NCT03425539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Study NCT01076218 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5
Description: This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
Study NCT03181724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them.
Study NCT03254329 — intervention group
Intervention type: OTHER
Intervention: Assessment of human milk nutrient composition
Description: Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
Study NCT04161755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
Study NCT04161755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7198457
Description: RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
Study NCT04161755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
Study NCT03547817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure device
Description: Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
Study NCT02272894 — intervention group
Intervention type: PROCEDURE
Intervention: Dissection of the Superior Mesenteric Vein Lymph Node
Description: 14v lymph node dissection
Study NCT02121041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg or 10 mg
Study NCT03561753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A (the standard 2HRZE/4HR regimen）
Description: The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
Study NCT01391013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir(DRV)
Description: Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
Study NCT04293432 — intervention group
Intervention type: DRUG
Intervention: Drugs, Generic
Description: All drugs having ≥10 TdP cases reported in the FAERS database
Study NCT02990702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided retroclavicular block
Description: Ultrasound guided retroclavicular block for forearm or hand surgery
Study NCT02990702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided coracoid infraclavicular block
Description: Ultrasound guided infraclavicular block for forearm or hand surgery
Study NCT02990702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02990702 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT03422133 — intervention group
Intervention type: OTHER
Intervention: Patient-oriented, personalized risk communication eHealth application
Description: The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
Study NCT05083156 — intervention group
Intervention type: OTHER
Intervention: Diet Change
Description: Observation Cohort will be observed for treatment response to elimination of cow's milk
Study NCT02121041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 12.5 mg or 25 mg
Study NCT02121041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg or 100 mg
Study NCT03561753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
Description: The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Study NCT01334879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 2.0 mg
Description: Intravitreal ranibizumab (2.0 mg)
Study NCT00979407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2340272A
Description: Two intramuscular injections at Day 0 and Day 21
Study NCT00979407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2340274A
Description: Two intramuscular injections at Day 0 and Day 21
Study NCT02881554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SC SPECT/CT
Study NCT03198078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (OPC-34712)
Description: Once-daily, tablets
Study NCT03198078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Once-daily, tablets
Study NCT01391013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
Study NCT02881554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SC SPECT/CT
Study NCT01391013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Description: 2 NRTIs will be administered as per the package inserts.
Study NCT02881554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Given IV
Study NCT02055339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel heated humidified high flow nasal cannula
Study NCT02055339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InfantFlow/RAM nasal continuous positive airway pressure
Study NCT01435356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recMAGE-A3 + AS15 ASCI
Description: 5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
Study NCT03198078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily, tablets
Study NCT01400165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
Study NCT01435356 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
Study NCT01400165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
Study NCT01400165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pindolol
Description: each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
Study NCT01400165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
Study NCT01166646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Proprionate Lotion 0.05%
Description: Apply 3.5 grams twice daily for 1-2 weeks
Study NCT01166646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Halobetasol Proprionate Cream 0.05%
Description: Apply 3.5 grams twice daily for 1-2 weeks
Study NCT02689557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: plethysmography
Description: Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
Study NCT03075228 — intervention group
Intervention type: DEVICE
Intervention: IntelliCap
Description: Sampling of the small intestine using a samling capsule.
Study NCT01143441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAC-HYP
Study NCT00860444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Educational and Counseling Program
Description: Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
Study NCT00860444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Educational and Counseling Program
Description: Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
Study NCT04720001 — intervention group
Intervention type: DRUG
Intervention: Florbetaben F18
Description: A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
Study NCT04720001 — intervention group
Intervention type: DEVICE
Intervention: PET
Description: PET Scan for brain imaging
Study NCT02314494 — intervention group
Intervention type: BEHAVIORAL
Intervention: ProAsk
Description: The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
Study NCT04888533 — intervention group
Intervention type: OTHER
Intervention: EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool
Description: EHSSA will be used to evaluate every patient for suicide risk.
Study NCT04201795 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laser
Description: laser with no emision will applied
Study NCT04201795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure and traction tecnique
Description: pressure and traction in plantar fascia with hands will be applied
Study NCT04692584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lullaby Group
Description: Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration.
Study NCT03310086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional fixed appliance
Description: aligning and leveling of lower anterior teeth using traditional fixed appliance.
Study NCT03310086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
Study NCT02767934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies